- Conditions
- NSCLC (Non-small Cell Lung Carcinoma), UC (Urothelial Cancer)
- Interventions
- Epacadostat, Atezolizumab
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 6
- States / cities
- Scottsdale, Arizona • New Haven, Connecticut • Boston, Massachusetts + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–96
of 408
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Lymphoma
- Interventions
- Parsaclisib
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 33
- States / cities
- Birmingham, Alabama • Tempe, Arizona • Redondo Beach, California + 27 more
- Conditions
- Solid Tumors
- Interventions
- INCB161734, Cetuximab, Retifanlimab, GEMNabP, mFOLFIRINOX, FOLFOX, FOLFIRI, INCA33890
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 710 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Palo Alto, California • Santa Monica, California + 9 more
- Conditions
- Chronic Graft-versus-host-disease
- Interventions
- Itacitinib, Extracorporeal Photopheresis (ECP)
- Drug · Device
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Advanced Solid Tumor, MSI-H/dMMR Tumors, Cutaneous Squamous Cell Carcinoma, Urothelial Carcinoma, Cervical Cancer, HepatoCellular Carcinoma, Esophageal Squamous Cell Carcinoma, Merkel Cell Carcinoma, Small-cell Lung Cancer, Mesothelioma, PD-L1 Amplified Tumor (9p24.1), Nasopharyngeal Carcinoma
- Interventions
- INCB099280
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 182 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 5
- States / cities
- Boston, Massachusetts • Detroit, Michigan • Pittsburgh, Pennsylvania + 2 more
- Conditions
- Solid Tumors and Hematologic Malignancy
- Interventions
- INCB054329 Monotherapy
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 12
- States / cities
- Los Angeles, California • San Francisco, California • Denver, Colorado + 8 more
- Conditions
- Hematologic Malignancies
- Interventions
- Itacitinib, Calcineurin inhibitor
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 9
- States / cities
- Aurora, Colorado • Atlanta, Georgia • Maywood, Illinois + 6 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- Itacitinib, Itacitinib Placebo
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 17
- States / cities
- Palm Desert, California • Pasadena, California • Lake Mary, Florida + 14 more
- Conditions
- Soft Tissue Sarcoma, Sarcoma,Soft Tissue, Sarcoma, Soft Tissue Sarcoma Adult
- Interventions
- Retifanlimab, Gemcitabine, Docetaxel
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Bronchiolitis Obliterans Syndrome
- Interventions
- Itacitinib
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Boston, Massachusetts • Durham, North Carolina + 3 more
- Conditions
- Myelodysplastic Syndromes, Multiple Myeloma, Anemia
- Interventions
- INCB000928
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 8
- States / cities
- Palo Alto, California • Miami, Florida • Sarasota, Florida + 5 more
- Conditions
- Solid Tumors, Advanced Malignancies, Metastatic Cancer
- Interventions
- INCB052793, gemcitabine, nab-paclitaxel, dexamethasone, Carfilzomib, bortezomib, lenalidomide, azacitidine, pomalidomide, INCB050465, INCB039110
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • West Hollywood, California • New Haven, Connecticut + 10 more
- Conditions
- Atopic Dermatitis
- Interventions
- Ruxolitinib cream, Vehicle
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 12 Years to 70 Years
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Culver City, California
- Conditions
- Non-sclerotic Cutaneous Chronic Graft-versus-host Disease
- Interventions
- topical ruxolitinib 1.5% cream, Topical vehicle/moisturizer cream
- Drug · Other
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Prurigo
- Interventions
- Ruxolitinib Cream, Vehicle Cream
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 204 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 18
- States / cities
- Phoenix, Arizona • Fort Smith, Arkansas • Fountain Valley, California + 15 more
- Conditions
- Psoriasis
- Interventions
- Placebo Cream, Ruxolitinib Phosphate
- Other · Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 199 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 28
- States / cities
- Hot Springs, Arkansas • Los Angeles, California • San Diego, California + 25 more
- Conditions
- Graft-versus-host Disease (GVHD)
- Interventions
- Itacitinib (200 mg), Itacitinib (300 mg), prednisone or methylprednisolone (corticosteroids)
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 23
- States / cities
- Duarte, California • La Jolla, California • Los Angeles, California + 20 more
- Conditions
- Metastatic Head and Neck Squamous Cell Carcinoma, Advanced Malignancies, Recurrent Head and Neck Squamous Cell Carcinoma
- Interventions
- INCAGN01876, retifanlimab
- Biological
- Lead sponsor
- Incyte Biosciences International Sàrl
- Industry
- Eligibility
- 18 Years to 99 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • La Jolla, California • Palo Alto, California + 14 more
- Conditions
- MPN (Myeloproliferative Neoplasms)
- Interventions
- Not listed
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,469 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 114
- States / cities
- Huntsville, Alabama • Tempe, Arizona • Tucson, Arizona + 111 more
- Conditions
- Atopic Dermatitis
- Interventions
- Ruxolitinib cream
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 12 Years to 65 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 9
- States / cities
- Anaheim, California • Encino, California • Miami, Florida + 6 more
- Conditions
- Solid Tumor
- Interventions
- Epacadostat, Pembrolizumab, Oxaliplatin, Leucovorin, 5-Fluorouracil, Gemcitabine, nab-Paclitaxel, Carboplatin, Paclitaxel, Pemetrexed, Cyclophosphamide, Cisplatin, Investigator's choice of platinum agent
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 16
- States / cities
- Phoenix, Arizona • La Jolla, California • Los Angeles, California + 12 more
- Conditions
- Myeloproliferative Neoplasm (MPN)
- Interventions
- Ruxolitinib
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2018
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Glioblastoma, Adult-type Diffuse Gliomas
- Interventions
- Pemigatinib
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 32
- States / cities
- Beverly Hills, California • Duarte, California • Fullerton, California + 28 more
- Conditions
- Advanced Malignancies
- Interventions
- INCA32459-101
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Houston, Texas